Predictive Impact of Peripheral Blood Lymphocytes on clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Abemaciclib (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary)
- Indications HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PALMARES-2
Most Recent Events
- 14 Mar 2025 Status changed from completed to recruiting.
- 09 Jul 2024 New trial record
- 04 Jun 2024 Results(With a data cut-off date of January 1st, 2024, n=1850) discussing antitumor efficacy , presented at the 60th Annual Meeting of the American Society of Clinical Oncology